Unraveling therapeutic targets in acute myeloid leukemia through multiplexed genome editing CRISPR screening

Figures & data

Figure 1. The illustration depicts the experimental procedures of in vitro, in vivo and single cell screens.

Table 1. Representative in vitro and in vivo CRISPR screens pertaining to AML.

	Reference	Gene Identified	Cells	gRNA library
In vitro	Tzelepis, et al. 2016, Cell Rep [5]	KAT2A	Human AML cell lines (MOLM-13, MV4–11, HL-60, OCI-AML2, and OCI-AML3), colon cancer cell line HT-29, and fibrosarcoma cell line HT-1080	18,010 genes 90,709 gRNAs
	Wang, et al. 2021, Cell Stem Cell [6]	ZFP36L2	Human AML cell lines (MOLM-13)	19,115 genes, 77,441 sgRNAs
	Aubrey, et al. 2022, Nat Cancer [7]	IKZF1	Human MLL-r AML cell lines (MOLM-13, MV4–11, OC-AML2 and THP-1)	18,000 genes, 185,634 sgRNAs
	Takacs, et al. 2019, Blood [8]	PIK3C3, DHODH, and Crkl	15 AML cell lines	Model-based Analysis GeCKO
	Hou, et al. 2017, Cancer Res [9]	SPRY3, GSK3	Human AML cell line (MV4–11)	18,080 genes 64,751 gRNAs
	Ling, et al. 2023, Leukemia [10]	CDKN2A, CHEK2, and TP53	Human AML cell lines (OCI-ALM3 and MV4–11)	19,114 genes 76,441 gRNAs
In vivo	Mercier, et al. 2022, Blood Adv [11]	Fermt3	Murine leukemic cell lines	72 genes, Mouse GeCKO v2
	Lin, et al. 2022, Cancer Discov [12]	SLC53 and MARCH5	AML cell lines (MV4–11, U937, and PDX16–01)	200 genes, 1320 sgRNAs
Single cell CRISPR screen	Wessels, et al. 2023, Nat Methods [15]	26 genes that influenced differentiation	Human AML cell lines (THP-1)	439 genes, 4390 gRNAs

Note: GeCKO: Genome-scale CRISPR-Cas9 Knockout library; sgRNA: Single guide RNA.

Tzelepis K, Koike-Yusa H, De Braekeleer E, et al. A CRISPR dropout screen identifies genetic vulnerabilities and therapeutic targets in acute myeloid leukemia. Cell Rep. 2016;17(4):1193–1205. doi: 10.1016/j.celrep.2016.09.079

 PubMed Web of Science ®Google Scholar

Wang E, Zhou H, Nadorp B, et al. Surface antigen-guided CRISPR screens identify regulators of myeloid leukemia differentiation. Cell Stem Cell. 2021;28(4):718–731. doi: 10.1016/j.stem.2020.12.005

 PubMed Web of Science ®Google Scholar

Aubrey BJ, Cutler JA, Bourgeois W, et al. IKAROS and MENIN coordinate therapeutically actionable leukaemogenic gene expression in MLL-r acute myeloid leukaemia. Nat Cancer. 2022;3(5):595–613. doi: 10.1038/s43018-022-00366-1

 PubMedGoogle Scholar

Takacs G, Zhou Y, King DJ, et al. CRISPR dropout screens identify DHODH, PIK3C3, and crkl as potential therapeutic targets in acute myeloid leukemia. Blood. 2019;134(Supplement_1):1452. doi: 10.1182/blood-2019-128180

 Web of Science ®Google Scholar

Hou PP, Wu C, Wang YC, et al. A genome-wide CRISPR screen identifies genes critical for resistance to FLT3 inhibitor AC220. Cancer Res. 2017;77(16):4402–4413. doi: 10.1158/0008-5472.CAN-16-1627

 PubMed Web of Science ®Google Scholar

Ling VY, Straube J, Godfrey W, et al. Targeting cell cycle and apoptosis to overcome chemotherapy resistance in acute myeloid leukemia. Leukemia. 2023;37(1):143–153. doi: 10.1038/s41375-022-01755-2

 PubMed Web of Science ®Google Scholar

Mercier FE, Shi JT, Sykes DB, et al. In vivo genome-wide CRISPR screening in murine acute myeloid leukemia uncovers microenvironmental dependencies. Blood Adv. 2022;6(17):5072–5084. doi: 10.1182/bloodadvances.2022007250

 PubMed Web of Science ®Google Scholar

Lin S, Larrue C, Scheidegger NK, et al. An in vivo CRISPR screening platform for prioritizing therapeutic targets in AML. Cancer Discov. 2022;12(2):432–449. doi: 10.1158/2159-8290.CD-20-1851

 PubMed Web of Science ®Google Scholar

Wessels HH, Méndez-Mancilla A, Hao YH. Efficient combinatorial targeting of RNA transcripts in single cells with Cas13 RNA Perturb-seq. Nat Methods. 2023;20(1):86–94. doi: 10.1038/s41592-022-01705-x

 PubMed Web of Science ®Google Scholar